Vetting frameworks
Structured prompts help assess medical screening, emergency planning, medication review, consent, aftercare claims, and disclosure. For foundational context, see what ibogaine therapy is described as before comparing any program.
Signal / information services
Services
Practical, evidence-first tools for evaluating ibogaine treatment claims, safety practices, and transparency before considering high-risk, unregulated care.
Violet Switch is an independent resource for people considering ibogaine, their families, and advocates. It does not provide treatment or make clinical recommendations.
01 / Orientation
A checklist before a commitment
Ibogaine treatment centers can present very different claims, settings, screening practices, and levels of transparency. Our ibogaine treatment evaluation guidance is designed to help people slow down, identify gaps, and keep the focus on verifiable safety information rather than marketing language.
Context matters because ibogaine is associated with serious cardiac risk. The FDA drug review process illustrates why evidence, monitoring, and disclosed risks matter when evaluating health-related claims, especially where care is unregulated.
Our approach is grounded in the principles described on how Violet Switch evaluates information: independent judgment, transparent standards, plain language, and informed consent.
02 / Information offerings
Tools for clearer questions
Comparison guidance
We explain how to compare stated protocols without treating rankings or testimonials as proof. A scan of claimed top ibogaine treatment centers can be a starting point for questions, not a substitute for independent verification.
Research summaries
Plain-language summaries separate early research, anecdotal reports, and unanswered questions. When considering reported outcomes, examine how ibogaine success rates are framed, including what the measure includes and what it leaves out.
Practical reference guides
Legal status, source material, travel, and expectations can shape decisions. The distinctions between ibogaine plants and treatment claims deserve careful attention, as do reports about an ibogaine trip experience, which are not evidence of safety or suitability.
03 / Signal test
What the checklist asks you to verify
- Whether the center clearly explains its screening process, contraindications, medication review, and the limits of what it can safely manage.
- Whether cardiac monitoring, emergency plans, transfer arrangements, and staff roles are described in concrete terms rather than broad reassurance.
- Whether consent materials distinguish known risks, uncertain outcomes, and personal stories from established evidence.
- Whether aftercare promises are specific, transparent, and realistic about the need for independent support.
Legal claims should be checked separately from medical claims. The question of whether ibogaine is illegal in the USA may affect practical decisions, but it does not establish whether a particular setting is safe or appropriate.
Specialized claims also need specialized scrutiny. Information marketed around ibogaine therapy for PTSD should be assessed against the center’s stated screening and follow-up practices, not assumed from the condition named in an advertisement.
Where supply is discussed, distinguish treatment operations from material sales. A reference to ibogaine plant seeds does not answer questions about medical oversight, monitoring, or quality controls in a treatment environment.
04 / FAQ channel
Common decision questions
Is a polished website evidence of a safe program?
No. Presentation can communicate a claim, but it cannot verify screening, monitoring, emergency readiness, or informed consent. Ask for clear answers that can be independently examined.
Why focus so closely on cardiac risk?
Because safety claims require more than general reassurance. Ibogaine’s documented background includes concern about effects on cardiac rhythm, which makes concrete screening and monitoring questions especially important.
Can personal stories establish likely outcomes?
No. Personal accounts can describe an individual experience, but they do not show who was screened out, what harms occurred, or whether an outcome lasts. This resource helps distinguish those questions from promotional narratives.
05 / Next signal
Use questions that keep risk in view.
Violet Switch provides practical, evidence-first tools for assessing ibogaine treatment claims, safety practices, and transparency. Start with the focused vetting checklist, then use the safety and cardiac-risk guidance before relying on a center’s claims.
Open the vetting checklist ↗